Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-24T14:05:00.309Z Has data issue: false hasContentIssue false

48 - Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development

from Section 7 - Funding and Financing Alzheimer’s Disease Drug Development

Published online by Cambridge University Press:  03 March 2022

By
Pragati Katiyar ,
Armineh L. Ghazarian ,
Zane Martin  and
Todd Haim
Edited by
Jeffrey Cummings ,
Jefferson Kinney  and
Howard Fillit
Jeffrey Cummings
Affiliation:
University of Nevada, Las Vegas
Jefferson Kinney
Affiliation:
University of Nevada, Las Vegas
Howard Fillit
Affiliation:
Alzheimer’s Drug Discovery Foundation
Get access

Summary

Early-stage drug development efforts for Alzheimer’s disease (AD) therapeutics often occur within academia and start-up companies and are often supported by National Institutes of Health (NIH) funding. The National Institute on Aging’s (NIA’s) seed funding through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide innovators with non-dilutive funding that supports key early-stage drug developments. Since 2015, the NIA small business funding programs have become a valuable source of seed funding available that enabled start-up companies to reach critical value inflection points. This chapter includes examples of five companies that received NIA small business funding at the preclinical stage of development and advanced their innovations to clinical trials: AgeneBio, Alector, Avid Radiopharmaceuticals, Cognition Therapeutics and Tetra Therapeutics. The NIH and NIA have launched several strategic initiatives and funding opportunities to enable small businesses to reach key value inflection points.

Keywords

National Institute on Aging (NIA)Alzheimer’s diseasesmall businessnon-dilutive fundingdrug developmenttherapeuticsseed fundingSBIRand STTR.
Type
Chapter
Information
Alzheimer's Disease Drug Development
Research and Development Ecosystem
 , pp. 533 - 543
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Deb, A, Thornton, JD, Sambamoorthi, U, Innes, K. Direct and indirect cost of managing Alzheimer’s disease and related dementias in the United States. Expert Rev Pharmacoecon Outcomes Res 2017; 17: 189–202.CrossRefGoogle ScholarPubMed
Hurd, MD, Martorell, P, Delavande, A, Mullen, KJ, Langa, KM. Monetary costs of dementia in the United States. N Engl J Med 2013; 368: 1326–34.Google Scholar
US Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. National plans to address Alzheimer’s disease. 2012. Available at: https://aspe.hhs.gov/napa-national-plans (accessed December 7, 2021).Google Scholar
Ghazarian, A, Haim, T, Sauma, S, Katiyar, P. National Institute on Aging seed funding enables Alzheimer’s disease startups to reach key value inflection points. Alzheimers Dement 2021;DOI: https://doi.org/10.1002/alz.12392.Google Scholar
Mauricio, R, Benn, C, Davis, J, et al. Therapeutics for dementia: tackling gaps in developing life-changing treatments for dementia. Alzheimers Dement (N Y) 2019; 5: 241–53.Google ScholarPubMed
Scott, TJ, O’Connor, AC, Link, AN, Beaulieu, TJ. Economic analysis of opportunities to accelerate Alzheimer’s disease research and development. Ann N Y Acad Sci 2014; 1313: 17–34.Google Scholar
Cummings, J, Reiber, C, Kumar, P. The price of progress: funding and financing Alzheimer’s disease drug development. Alzheimers Dement (N Y) 2018; 4: 330–43.Google Scholar
US Small Business Administration. Birth and history of the SBIR program. Available at: www.sbir.gov/birth-and-history-of-the-sbir-program (accessed November 10, 2021).Google Scholar
Onken, J, Miklos, AC, Dorsey, TF, et al. Using database linkages to measure innovation, commercialization, and survival of small businesses. Eval Program Plann 2019; 77: 101710.Google Scholar
US Small Business Administration. About SBA. Available at: www.sba.gov/about-sba (accessed November 3, 2020).Google Scholar
US Small Business Administration. Performance benchmark requirements for Phase I. Available at: www.sbir.gov/performance-benchmarks (accessed November 10, 2020).Google Scholar
National Science Board. Science and Engineering Indicators. 2018: research and development – US trends and international comparisons. Available at: www.nsf.gov/statistics/2018/nsb20181/ (accessed November 10, 2020).Google Scholar
Jefferson, RS. How the largest public funder of biomedical research in the world spends your money. Available at: www.forbes.com/sites/robinseatonjefferson/2018/12/21/how-the-largest-public-funder-of-biomedical-research-in-the-world-spends-your-money/?sh=69d3d48f27b9 (accessed November 23, 2020).Google Scholar
NIH Research Portfolio Online Reporting Tools (RePORT). Small business research (SBIR/STTR). Available at: https://report.nih.gov/nihdatabook/category/8 (accessed November 23, 2020).Google Scholar
National Institutes of Health. Intellectual property and iEdison invention report requirements. Available at: https://sbir.nih.gov/policy/invention-reporting (accessed December 2, 2020).Google Scholar
Ben-Menachem, G, Ferguson, SM, Balakrishnan, K. Doing business with the NIH. Nat Biotechnol 2006; 24: 17–20.Google Scholar
National Institutes of Health. Advancing research on Alzheimer’s disease (AD) and Alzheimer’s-disease-related dementias (ADRD) (R41/R42). Available at: https://grants.nih.gov/grants/guide/pa-files/PAs-17-065.html (accessed November 10, 2020).Google Scholar
National Institutes of Health. Advancing research on Alzheimer’s disease (AD) and Alzheimer’s-disease-related dementias (ADRD) (R43/R44). Available at: https://grants.nih.gov/grants/guide/pa-files/PAs-17-064.html (accessed November 10, 2020).Google Scholar
Cole, MA, Seabrook, GR. On the horizon: the value and promise of the global pipeline of Alzheimer’s disease therapeutics. Alzheimers Dement (N Y) 2020; 6: e12009.Google Scholar
Bakker, A, Krauss, GL, Albert, MA, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 2012; 74: 467–74.Google Scholar
Cognition Therapeutics. Cognition Therapeutics receives $75.8 million NIA grant for 540-patient Phase 2 study of CT1812 in collaboration with the Alzheimer’s Clinical Trials Consortium. Available at: https://cogrx.com/cognition-receives-nia-grant-for-actc-study/ (accessed December 2, 2020).Google Scholar
Businesswire. Tetra Therapeutics and Shionogi announce expanded alliance. Available at: www.businesswire.com/news/home/20200306005082/en/Tetra-Therapeutics-Shionogi-Announce-Expanded-Alliance (accessed December 2, 2021).Google Scholar
Canaria, CA, Portilla, L, Weingarten, M. I-Corps at NIH: entrepreneurial training program creating successful small businesses. Clin Transl Sci 2019; 12: 324–8.CrossRefGoogle ScholarPubMed
Cummings, J, Lee, G, Ritter, A, Sabbagh, M, Zhong, K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement (N Y) 2019; 5: 272–93.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×